Page 1

CRISPRI THERAPEUTICS CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110 ™ in Relapsed or Refractory CD19 + B - cell malignancies -58 % overall response rate ( ORR ) and 38 % complete response ( CR ) rate in large B - cell lymphoma ( LBCL ) with a single dose of CTX110 at Dose Level 2 ( DL2 ) and above on an intent - to - treat ( ITT ) basis -Durable responses in LBCL achieved with six - month CR rate of 21 % and longest response on - going at over 18 months after initial infusion -Response rates and durability are similar to approved autologous CD19 CAR - T therapies on an ITT basis -Positively differentiated safety profile ; no Grade 3 or higher cytokine release syndrome ( CRS ) and low rates of infection and Immune Effector Cell - Associated Neurotoxicity Syndrome ( ICANS ) -Expanding CARBON into a potentially registrational trial in 1Q 2022 -Management to host webcast and conference call today at 4:30 PM ET ZUG , Switzerland and CAMBRIDGE , Mass . , October 12 , 2021 -- CRISPR Therapeutics ( Nasdaq : CRSP ) , a biopharmaceutical company focused on creating transformative gene - based medicines for serious diseases , today announced updated results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110TM , its wholly - owned allogeneic CAR - T cell therapy targeting CD19 + B - cell malignancies . " We are excited to share positive data from our CARBON trial , which show that CTX110 could offer patients with large B - cell lymphomas an immediately available ' off - the - shelf ' therapy with efficacy similar to autologous CAR - T and a differentiated safety profile , ” said Samarth Kulkarni , Ph.D. , Chief Executive Officer of CRISPR Therapeutics . " Furthermore , we have the potential to improve upon already observed efficacy with a consolidation dosing strategy . Based on these encouraging results , we are planning to expand CARBON into a potentially registrational trial in the first quarter of 2022. " CARBON Trial Overview The Phase 1 CARBON trial is an open - label , multicenter clinical trial evaluating the safety and efficacy of CTX110 in adult patients with relapsed or refractory B - cell CD19 + malignancies who have received at least two prior lines of therapy . To date , enrollment has been focused on patients with the most aggressive disease presentations , including diffuse large B - cell lymphoma ( DLBCL ) , not otherwise specified ( NOS ) , high - grade double- or triple - hit lymphomas , and transformed follicular lymphoma . The majority of patients had Stage IV lymphoma and were refractory to their last line of therapy before entering the trial . Nine patients received prior autologous stem cell transplant . Patients who received prior autologous CAR T therapy were not eligible . As of the August 26 , 2021 data cutoff , 30 patients with large B - cell lymphoma ( LBCL ) had been enrolled , of which 26 patients had received CTX110 with at least 28 days of follow - up and are included in the analysis . Only one enrolled patient did not receive CTX110 . Three patients at the time of the data cut had less than 28 days of follow - up and were not evaluable for this analysis .